

Singapore deepens research collaboration in applied AI for drug discovery and life sciences

28 April 2025 | News

Signs MoU with ETH Zürich harnessing AI to accelerate and de-risk drug discovery



A*STAR and ETH Zürich have officially inked a Memorandum of Understanding (MOU) to deepen research collaboration in applied AI for drug discovery and life sciences.

As leaders in science and technology, both institutions are committed to harnessing AI to accelerate and de-risk drug discovery—making it faster, more targeted, and cost-effective. AI models support researchers in identifying potential new drug targets, propose novel molecules, and match them to patient populations more efficiently.

This partnership builds on existing efforts, including ETH Zürich's ETH | Cure initiative and A*STAR's growing capabilities in AI-driven drug discovery, led by the Bioinformatics Institute, A*STAR (A*STAR BII) and Experimental Drug Development Centre (EDDC), to develop cutting-edge tools to bring safer and more effective therapies to patients faster.

By combining strengths in data science, biology and translational research, this collaboration aims to deliver real-world impact in healthcare and beyond.